Christos Evangelou

Christos Evangelou

Auto-generated profile, based on publicly available information

Christos Evangelou

Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CWChun Wai Wong
Chun Wai Wong
CEChristos Evangelou
Christos Evangelou
KSKieran N. Sefton
Kieran N. Sefton
RLRotem Leshem
Rotem Leshem
WZWei Zhang
Wei Zhang
AHAdam Hurlstone
Adam Hurlstone
Resistance mechanisms to immune checkpoint blockade therapy (ICBT) limit its response duration and magnitude. Paradoxically, Interferon γ (IFNγ), a key cytokine for cellular immunity, can promote ICBT resistance. Using syngeneic mouse tumour models, we confirm that chronic IFNγ exposure confers resistance to immunotherapy targeting PD-1 (α-PD-1) in immunocompetent female mice. We observe upregulation of poly-ADP ribosyl polymerase 14 (PARP14) in chronic IFNγ-treated cancer cell models, in patient melanoma with elevated IFNG expression, and in melanoma cell cultures from ICBT-progressing lesions characterised by elevated IFNγ signalling. Effector T cell infiltration is enhanced in tumours derived from cells pre-treated with IFNγ in immunocompetent female mice when PARP14 is pharmacologically inhibited or knocked down, while the presence of regulatory T cells is decreased, leading to restoration of α-PD-1 sensitivity. Finally, we determine that tumours which spontaneously relapse in immunocompetent female mice following α-PD-1 therapy upregulate IFNγ signalling and can also be re-sensitised upon receiving PARP14 inhibitor treatment, establishing PARP14 as an actionable target to reverse IFNγ-driven ICBT resistance.

1 May 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FHFiona Henderson
Fiona Henderson
HJHannah R. Johnston
Hannah R. Johnston
ABAndrew P. Badrock
Andrew P. Badrock
EJEmrys A. Jones
Emrys A. Jones
DFDuncan Forster
Duncan Forster
AHAdam Hurlstone
Adam Hurlstone
Alterations in lipid metabolism in cancer cells impact cell structure, signaling, and energy metabolism, making lipid metabolism a potential diagnostic marker and therapeutic target. In this study, we combined PET, desorption electrospray ionization-mass spectrometry (DESI-MS), nonimaging MS, and transcriptomic analyses to interrogate changes in lipid metabolism in a transgenic zebrafish model of oncogenic RAS-driven melanocyte neoplasia progression. Exogenous fatty acid uptake was detected in melanoma tumor nodules by PET using the palmitic acid surrogate tracer 14(R,S)-18F-fluoro-6-thia-heptadecanoic acid ([18F]-FTHA), consistent with upregulation of genes associated with fatty acid uptake found through microarray analysis. DESI-MS imaging revealed that FTHA uptake in tumors was heterogeneous. Transcriptome and lipidome analyses further highlighted dysregulation of glycerophospholipid pathways in melanoma tumor nodules, including increased abundance of phosphatidyl ethanolamine and phosphatidyl choline species, corroborated by DESI-MS, which again revealed heterogeneous phospholipid composition in tumors. Overexpression of the gene encoding lipoprotein lipase (LPL), which was upregulated in zebrafish melanocyte tumor nodules and expressed in the majority of human melanomas, accelerated progression of oncogenic RAS-driven melanocyte neoplasia in zebrafish. Depletion or antagonism of LPL suppressed human melanoma cell growth; this required simultaneous fatty acid synthase (FASN) inhibition when FASN expression was also elevated. Collectively, our findings implicate fatty acid acquisition as a possible therapeutic target in melanoma, and the methods we developed for monitoring fatty acid uptake have potential for diagnosis, patient stratification, and monitoring pharmacologic response. Significance: These findings demonstrate the translational potential of monitoring fatty acid uptake and identify lipoprotein lipase as a potential therapeutic target in melanoma.

26 May 2018 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
AKAthanasios Karapetsas
Athanasios Karapetsas
MTMaria Tokamani
Maria Tokamani
CEChristos Evangelou
Christos Evangelou
RSRaphael Sandaltzopoulos
Raphael Sandaltzopoulos

13 March 2018 in OncoImmunology
Verified
Journal Article
Closed access
MGMareike Grees
Mareike Grees
ASAdi Sharbi-Yunger
Adi Sharbi-Yunger
CEChristos Evangelou
Christos Evangelou
DBDaniel Baumann
Daniel Baumann
GCGal Cafri
Gal Cafri
VUViktor Umansky
Viktor Umansky
Despite melanoma immunogenicity and remarkable therapeutic effects of negative immune checkpoint inhibitors, a significant fraction of patients does not respond to current treatments. This could be due to limitations in tumor immunogenicity and profound immunosuppression in the melanoma microenvironment. Moreover, insufficient tumor antigen processing and presentation by dendritic cells (DC) may hamper the development of tumor-specific T cells. Using two genetically engineered mouse melanoma models (RET and BRAFV600E transgenic mice), in which checkpoint inhibitor therapy alone is not efficacious, we performed proof-of-concept studies with an improved, multivalent DC vaccination strategy based on our recently developed genetic mRNA cancer vaccines. The in vivo expression of multiple chimeric MHC class I receptors allows a simultaneous presentation of several melanoma-associated shared antigens tyrosinase related protein (TRP)-1, tyrosinase, human glycoprotein 100 and TRP-2. The DC vaccine induced a significantly improved survival in both transgenic mouse models. Vaccinated melanoma-bearing mice displayed an increased CD8 T cell reactivity indicated by a higher IFN-γ production and an upregulation of activation marker expression along with an attenuated immunosuppressive pattern of myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg). The combination of DC vaccination with ultra-low doses of paclitaxel or anti-PD-1 antibodies resulted in further prolongation of mouse survival associated with a stronger reduction of MDSC and Treg immunosuppressive phenotype. Our data suggest that an improved multivalent DC vaccine based on shared tumor antigens induces potent anti-tumor effects and could be combined with checkpoint inhibitors or targeting immunosuppressive cells to further improve their therapeutic efficiency.

1 January 2017 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
IBIoannis Bakoyiannis
Ioannis Bakoyiannis
VCVeroniki Cherdyntseva
Veroniki Cherdyntseva
MAMaria Aivalioti
Maria Aivalioti
MBMaria Barton
Maria Barton
DCDavide Coda
Davide Coda
EZEfthalia Zafeiropoulou
Efthalia Zafeiropoulou

1 June 2018 in ESMO Open
Verified
Journal Article
Open access
PDF file
CEC. Evangelou
C. Evangelou
RNR. Nagaraju
R. Nagaraju
AHA. Hurlstone
A. Hurlstone
Introduction IFNγ is a key component of our immune system, regulating a plethora of biological processes, including antitumor immunity. Its role in tumour immunology is however contradictory, exerting anti-tumour effects early in tumour development but promoting tumour immune evasion and tumour development at later stages. Its involvement in immunotherapy resistance is also extremely complex and is potentially mediated through multiple cellular processes. In this study, we aimed to generate further insights into the role of sustained IFNγ signalling in acquired resistance to immune selection and immunotherapy. Material and methods A panel of established human and mouse melanoma cell lines were treated with increasing doses of IFNγ for 24 hour and the levels of IFNγ pathway activation were assessed by phospho-STAT1 immunoblotting. To assess the effects of chronic low-dose IFNγ treatment in gene expression of melanoma cell lines, RNA sequencing was performed in melanoma cell lines treated with INFγ for 2 weeks, followed by pathway analysis and gene set enrichment analysis of the differentially expressed genes. Finally, we assessed the DNA damage effects of chronic low-dose IFNγ treatment in melanoma cell lines by γH2AX immunofluorescent staining. Results and discussions We showed that established melanoma cell lines retain responsiveness to IFNγ, as reflected by the increased levels of phospho-STAT1 after treatment with increasing doses of IFNγ. Interestingly, RNAseq in melanoma cell lines chronically treated with low-dose IFNγ revealed oxidative stress response as well as DNA damage and repair pathways among the top upregulated pathways in IFNγ treated cells. In line with this, gene set enrichment analysis showed enrichment of DNA damage response and repair related signatures in genes upregulated by IFNγ treatment. Finally, we showed that chronic low-dose IFNγ treatment of melanoma cell lines induces DNA damage, as revealed by increased levels of γH2AX foci per cell and percentage of γH2AX positive cells. Conclusion In vitro chronic treatment of melanoma cells with low-dose IFNγ has been previously shown to make cells acquire an immunotherapy resistance phenotype. In this study we showed that chronic low-dose treatment of human and mouse melanoma cell lines induces DNA damage, as revealed by γH2AX immunofluorescent staining and RNAseq followed by pathway analysis. The role of IFNγ-driven constitutive DNA damage response in immune evasion and immunotherapy resistance merits further evaluation as an actionable therapeutic target.